Treatment of life-threatening digoxin toxicity with digoxin-specific antibody fragments: results from a prospective, non-interventional observational UK patient registry study

Digoxin is expected to remain a widely prescribed medication for atrial fibrillation and cardiovascular disorders generally. Digoxin toxicity can occur, and severe toxicity represents a medical emergency, with intravenous administration of digoxin-specific antibody fragments (DIF; DigiFab, Protheric...

Full description

Saved in:
Bibliographic Details
Published in:European journal of hospital pharmacy. Science and practice 2023-11, Vol.30 (6), p.e34-e34
Main Authors: Thomas, Emma, Tomlinson, Sam, Thomas, Siwan, Ward, Suzanne, Daugherty, Claire, Gallardo, Eva, Hill, Christon
Format: Article
Language:English
Subjects:
Antibodies
Cardiac arrhythmia
Demographics
DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS
EMERGENCY MEDICINE
Employees
Ethics
Heart failure
Hyperkalemia
Hypertension
Hypothermia
Kidneys
Marketing
Patients
PostScript
Regulatory agencies
Safety
Surveillance
Toxicity
Toxicology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Digoxin is expected to remain a widely prescribed medication for atrial fibrillation and cardiovascular disorders generally. Digoxin toxicity can occur, and severe toxicity represents a medical emergency, with intravenous administration of digoxin-specific antibody fragments (DIF; DigiFab, Protherics Medicines Development Ltd) indicated in the presence of life-threatening arrhythmias.1 2
ISSN:2047-9956
2047-9964
DOI:10.1136/ejhpharm-2022-003416